Oruka Therapeutics, Inc. (ORKA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6876041087
Oruka Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -122.05 m USD |
| EBIT | -122.06 m USD |
| Net income | -105.43 m USD |
Full history since 2005, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
More stocks
- Orange Polska SA (OPL.WA)
- PT Merdeka Gold Resources Tbk (EMAS.JK)
- China Energy Engineering Corp Ltd (3996.HK)
- Brookfield Renewable Corp (BEPC)
- PRICESMART INC (PSMT)
- NOVANTA INC (NOVT)
- Linktel Technologies Co. Ltd. A (301205.SZ)
- Cenergy Holdings SA (CENER.BR)
- Xinjiang Daqo New Energy Co Ltd (688303.SS)
- LAUREATE EDUCATION, INC. (LAUR)
- WHITE MOUNTAINS INSURANCE GROUP LTD (WTM)
- LG CNS (064400.KS)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.